Immix Biopharma, INC Form 4 insider transactions

Director Helen C. Adams acquired 6,250 restricted stock units and 12,500 stock options as part of an equity incentive plan.

Director Carey Ng was granted 6,250 restricted stock units and 12,500 stock options by Immix Biopharma, Inc.

Director Magda Marquet was granted 6,250 restricted stock units and 12,500 stock options by Immix Biopharma, Inc.

Immix Biopharma CFO and President Gabriel S. Morris was granted 500,000 stock options vesting over 48 months.

Director Nancy T. Chang was granted 6,250 restricted stock units and 12,500 stock options as part of the company's 2021 Equity Incentive Plan.

Immix Biopharma CEO and Chairman Ilya M. Rachman was granted 500,000 stock options vesting over 48 months.

Director Yekaterina Chudnovsky was granted 6,250 restricted stock units and 12,500 stock options by Immix Biopharma, Inc.

Director Jason Hsu was granted 6,250 restricted stock units and 12,500 stock options as part of the company's 2021 Equity Incentive Plan.

Director Jane Buchan was granted 6,250 restricted stock units and 12,500 stock options by Immix Biopharma, Inc.

Immix Biopharma Director Nancy T. Chang reported new stock option grants and updated beneficial ownership of common stock.

Immix Biopharma's CEO and Chairman, Ilya M. Rachman, purchased 746 shares of common stock at $6.67 per share as part of a Rule 10b5-1 plan.

Immix Biopharma's CFO, Gabriel S. Morris, increased his beneficial ownership through the exercise of warrants and an open market purchase of common stock.

Immix Biopharma's CEO and Chairman, Ilya Rachman, purchased 2,500 shares of common stock at an average price of $2.02 per share, increasing his direct beneficial ownership.

Immix Biopharma's CFO and Director, Gabriel S. Morris, acquired 2,600 shares of common stock at $1.97 per share.

Immix Biopharma, Inc. Director Carey Ng reported the acquisition of 33,000 stock options and updated his beneficial ownership of common stock.

Immix Biopharma, Inc. (IMMX) announced that its CFO and Director, Gabriel S. Morris, was granted 340,000 stock options with an exercise price of $2.24, vesting over 48 months.

Immix Biopharma, Inc. Director Magda Marquet has reported the acquisition of 33,000 stock options and updated her beneficial ownership of common stock, as detailed in a recent SEC Form 4 filing.

Immix Biopharma, Inc. Director Jason Hsu has filed a Form 4 detailing his beneficial ownership of common stock and the acquisition of new stock options.

Immix Biopharma, Inc. Director Helen C. Adams was granted 33,000 stock options with an exercise price of $2.24, vesting over twelve months, as disclosed in a recent SEC Form 4 filing.

Immix Biopharma, Inc. Director Jane Buchan reported the acquisition of 33,000 stock options with an exercise price of $2.24, vesting monthly over one year, alongside her existing direct ownership of 22,455 common shares.

Immix Biopharma, Inc. Director and 10% Owner Yekaterina Chudnovsky has reported an indirect beneficial ownership of over 3.2 million common shares and the grant of 33,000 stock options.

Immix Biopharma, Inc. CEO and Chairman Ilya M. Rachman was granted 340,000 stock options with an exercise price of $2.24, vesting over 48 months, as disclosed in a recent SEC Form 4 filing.

Immix Biopharma's CEO and Chairman, Ilya Rachman, recently purchased 2,178 shares of the company's common stock, increasing his beneficial ownership.

Immix Biopharma's CFO and Director, Gabriel S. Morris, reported the acquisition of 2,225 shares of common stock on June 18, 2025, increasing his direct and indirect beneficial ownership in the company.

Director Jason Hsu reports purchasing additional shares of Immix Biopharma, Inc. in two transactions.

Director Jason Hsu of Immix Biopharma, Inc. [IMMX] recently purchased shares of common stock in two transactions on August 21 and August 22, 2024.

Director Carey Ng reports purchasing 10,000 shares of Immix Biopharma at an average price of $1.86 and disposing of 20,000 shares.

Director Jason Hsu of Immix Biopharma, Inc. reports purchasing shares of common stock in two transactions this month.

Director Magda Marquet reports acquisition of stock options and changes in beneficial ownership of Immix Biopharma, Inc. shares.

Yekaterina Chudnovsky, a director of Immix Biopharma, Inc., acquired 33,000 stock options on June 11, 2024.